# Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)

> **NCT03669523** · PHASE2 · COMPLETED · sponsor: **Centre Hospitalier Annecy Genevois** · enrollment: 82 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Bone Metastases

## Interventions

- **DRUG:** Denosumab-nivolumab combination

## Key facts

- **NCT ID:** NCT03669523
- **Lead sponsor:** Centre Hospitalier Annecy Genevois
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-06
- **Primary completion:** 2023-10-19
- **Final completion:** 2023-10-19
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2025-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03669523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03669523, "Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03669523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*